Evidence map›Paper›PMID 33302537›Full record

ReviewMolecules (Basel, Switzerland)2020

Metal Nanoparticles for Electrochemical Sensing: Progress and Challenges in the Clinical Transition of Point-of-Care Testing.

Tamanna Islam, Md Mahedi Hasan, Abdul Awal, Md Nurunnabi, A J Saleh Ahammad

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 69 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Graphite nanocrystals coated paper-based electrode for detection of SARS-Cov-2 gene using DNA-functionalized Au@carbon dot core-shell nanoparticles.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2022
    Article
  16. Technologies for Frugal and Sensitive Point-of-Care Immunoassays.Annual review of analytical chemistry (Palo Alto, Calif.) · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Tamanna IslamDepartment of Chemistry, Jagannath University, Dhaka 1100, Bangladesh.ORCID 0000-0001-9067-4372
Md Mahedi HasanDepartment of Chemistry, Jagannath University, Dhaka 1100, Bangladesh.ORCID 0000-0001-7683-4544
Abdul AwalDepartment of Chemistry, Jagannath University, Dhaka 1100, Bangladesh.
Md NurunnabiDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Texas at El Paso, El Paso, TX 79902, USA.
A J Saleh AhammadDepartment of Chemistry, Jagannath University, Dhaka 1100, Bangladesh.ORCID 0000-0001-7568-5268
Jagannath University · BDThe University of Texas at El Paso · US

Funding

Lizanell and Colbert Coldwell Foundation 226811530A
6 · The paper itself

Abstract

With the rise in public health awareness, research on point-of-care testing (POCT) has significantly advanced. Electrochemical biosensors (ECBs) are one of the most promising candidates for the future of POCT due to their quick and accurate response, ease of operation, and cost effectiveness. This review focuses on the use of metal nanoparticles (MNPs) for fabricating ECBs that has a potential to be used for POCT. The field has expanded remarkably from its initial enzymatic and immunosensor-based setups. This review provides a concise categorization of the ECBs to allow for a better understanding of the development process. The influence of structural aspects of MNPs in biocompatibility and effective sensor design has been explored. The advances in MNP-based ECBs for the detection of some of the most prominent cancer biomarkers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), Herceptin-2 (HER2), etc.) and small biomolecules (glucose, dopamine, hydrogen peroxide, etc.) have been discussed in detail. Additionally, the novel coronavirus (2019-nCoV) ECBs have been briefly discussed. Beyond that, the limitations and challenges that ECBs face in clinical applications are examined and possible pathways for overcoming these limitations are discussed.

Indexed as

Point-of-Care TestingBiomarkers, TumorBiosensing TechniquesCarbonCOVID-19 TestingElectrochemical TechniquesEquipment DesignFemaleHumansMaleMetal NanoparticlesNanostructuresBiomarkers, TumorCarboncancer biomarkerselectrochemical biosensorsglucosemetal nanoparticlesnovel coronaviruspoint-of-care testing

Identifiers

PMID33302537
PMCPMC7763225
OpenAlexW3112119080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.